Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR004
MIFTS: 53

Thrombocytosis

Categories: Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytosis

About this section

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 76 29 55 44 15 73
Thrombocythaemia 12

Classifications:

MalaCards categories:
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2228
MeSH 44 D013922
NCIt 50 C35530
SNOMED-CT 68 6631009 79574003
UMLS 73 C0836924
Sources

Summaries for Thrombocytosis

About this section
Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to thrombocythemia 1 and polycythemia vera. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Anagrelide and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and lung, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 76 Thrombocythemia (also thrombocytosis) is the presence of high platelet (thrombocyte) counts in the... more...

Sources

Related Diseases for Thrombocytosis

About this section

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 32.9 MPL THPO
2 polycythemia vera 31.9 EPO IL3 JAK2 MPL SELP TET2
3 essential thrombocythemia 31.8 EPO F2 F3 IL11 IL3 JAK2
4 blood platelet disease 30.8 F2 F3 JAK2 MPL SELP SERPINC1
5 refractory anemia 30.5 EPO IL3 JAK2 MPL TET2
6 iron deficiency anemia 30.4 CRP EPO IL6 THPO
7 myeloproliferative neoplasm 30.4 JAK2 MPL TET2
8 myeloid leukemia 30.3 CSF2 IL3 JAK2 TET2
9 splenomegaly 30.3 EPO JAK2 MPL
10 thrombocytopenia 30.2 F3 IL11 MPL THPO
11 polycythemia 30.2 EPO IL3 JAK2 MPL TET2 THPO
12 chromosome 5q deletion syndrome 30.2 EPO TET2
13 myelofibrosis 30.1 EPO IL3 JAK2 MPL TET2 THPO
14 poems syndrome 30.1 EPO IL6
15 deficiency anemia 30.0 CRP EPO IL11 IL3 IL6 THPO
16 thrombosis 29.8 F2 F3 JAK2 SELP SERPINC1
17 portal hypertension 29.8 F2 JAK2 THPO
18 myelodysplastic myeloproliferative cancer 29.8 CSF2 JAK2 TET2
19 leukemia, acute myeloid 29.8 CSF2 IL3 JAK2 MPL TET2 THPO
20 intracranial hypertension 29.7 F2 F3 SERPINC1
21 portal vein thrombosis 29.7 F2 JAK2 SELP SERPINC1
22 leukemia, chronic myeloid 29.6 CSF2 EPO IL3 JAK2 MPL THPO
23 central retinal vein occlusion 29.6 F2 IL6 SERPINC1
24 retinal vein occlusion 29.6 F2 IL6 SERPINC1
25 myelodysplastic syndrome 29.5 CSF2 EPO IL11 IL3 JAK2 MPL
26 coronary artery anomaly 29.5 CRP F2 SELP
27 budd-chiari syndrome 29.5 F2 F3 JAK2 SERPINC1
28 acute myocardial infarction 29.4 CRP F3 SELP SERPINC1
29 peritonitis 29.4 CRP F2 IL6
30 thrombocytopenic purpura, autoimmune 29.4 IL11 MPL SELP THPO
31 sagittal sinus thrombosis 29.4 F2 F3 SERPINC1
32 intracranial embolism 29.4 F2 SERPINC1
33 von willebrand's disease 29.3 F2 F3 SELP
34 myocardial infarction 29.3 CRP F2 F3 IL6 SELP SERPINC1
35 pulmonary embolism 29.3 CRP F2 F3 SERPINC1
36 thrombophilia due to thrombin defect 29.3 F2 F3 SERPINC1
37 nervous system disease 29.3 CRP CSF2 IL6
38 heparin-induced thrombocytopenia 29.3 F3 SERPINC1
39 pancytopenia 29.2 CSF2 EPO IL3 MPL THPO
40 megakaryocytic leukemia 29.2 CSF2 IL11 IL3 JAK2 THPO
41 monocytic leukemia 29.2 CSF2 F3 IL6
42 myeloma, multiple 29.2 CRP CSF2 EPO IL6 JAK2
43 thrombophilia due to activated protein c resistance 29.1 F2 F3 SERPINC1
44 thrombophilia 29.1 F2 F3 SERPINC1
45 hemorrhagic disease 29.0 F2 F3 MPL SERPINC1 THPO
46 purpura 29.0 CRP F2 F3 IL6 MPL SERPINC1
47 arteries, anomalies of 28.9 CRP F3 IL6 SELP SERPINC1
48 peripheral vascular disease 28.7 CRP F2 F3 IL6 SELP SERPINC1
49 vascular disease 28.6 CRP F2 F3 IL6 SELP SERPINC1
50 heart disease 28.4 CRP F2 F3 IL6 SELP SERPINC1

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis
Sources

Symptoms & Phenotypes for Thrombocytosis

About this section

MGI Mouse Phenotypes related to Thrombocytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 CSF2 EPO F2 F3 IL6 JAK2
2 cardiovascular system MP:0005385 10.11 CRP CSF2 EPO F2 F3 IL6
3 homeostasis/metabolism MP:0005376 10.11 CRP CSF2 EPO F2 F3 IL6
4 immune system MP:0005387 10.1 CRP CSF2 EPO F2 F3 IL6
5 embryo MP:0005380 9.98 CSF2 EPO F2 F3 JAK2 MPL
6 integument MP:0010771 9.8 CSF2 EPO F2 F3 IL6 JAK2
7 mortality/aging MP:0010768 9.65 CSF2 EPO F2 F3 IL6 JAK2
8 liver/biliary system MP:0005370 9.63 EPO IL6 JAK2 SELP SERPINC1 TET2
9 respiratory system MP:0005388 9.1 CSF2 EPO F2 F3 IL6 SELP
Sources

Drugs & Therapeutics for Thrombocytosis

About this section

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 270)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
3 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
5
Zinc Approved, Investigational Phase 4 7440-66-6
6
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-86-4 3871
7 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
9 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
12
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
13
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
14
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
15
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
16
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
17
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
18
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
19
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
20 Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
23
Dalteparin Approved Phase 3 9005-49-6
24
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
25
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
29
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
30
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
31
Ribavirin Approved Phase 3 36791-04-5 37542
32
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
33
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
34
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
35
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
36
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
37
Hydroxychloroquine Approved Phase 3 118-42-3 3652
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
39
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
40
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42 Anesthetics, Dissociative Phase 3
43 Anesthetics, General Phase 3
44 Excitatory Amino Acid Antagonists Phase 3
45 Excitatory Amino Acids Phase 3
46 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
47 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
48 Anesthetics, Intravenous Phase 3
49 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
8 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
9 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
11 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
12 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
13 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
14 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
15 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
16 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
17 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
18 High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) Completed NCT00050531 Phase 3 Gleevec;Peg-alpha interferon (Peg-Intron);Sargramostim (GM-CSF)
19 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
20 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
21 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
22 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
30 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
31 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
32 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
33 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
34 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
35 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Recruiting NCT01621204 Phase 3 Eltrombopag;IVIG infusion
36 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
37 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
38 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
39 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
40 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
41 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Not yet recruiting NCT03755518 Phase 3 FEDRATINIB
42 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
43 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
44 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
45 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
46 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
47 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
48 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
49 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
50 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thrombocytosis

Sources

Genetic Tests for Thrombocytosis

About this section

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 29
Sources

Anatomical Context for Thrombocytosis

About this section

MalaCards organs/tissues related to Thrombocytosis:

41
Myeloid, Bone, Lung, Liver, Bone Marrow, Spleen, Neutrophil
Sources

Publications for Thrombocytosis

About this section

Articles related to Thrombocytosis:

(show top 50) (show all 1382)
# Title Authors Year
1
Extreme reactive thrombocytosis in an infant: Much ado about nothing? ( 30251331 )
2019
2
The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis. ( 29654448 )
2018
3
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 29404744 )
2018
4
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report. ( 29851840 )
2018
5
Preliminary investigation about the expression of tubulin in platelets from patients with iron deficiency anemia and thrombocytosis. ( 29499633 )
2018
6
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. ( 29240268 )
2018
7
Essential thrombocytosis 40 years after splenectomy. ( 29602892 )
2018
8
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
9
Factors associated with ultrasound-guided water enema reduction for pediatric intussusception in resource-limited setting: potential predictive role of thrombocytosis and anemia. ( 29459045 )
2018
10
Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. ( 29368262 )
2018
11
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. ( 29282219 )
2018
12
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy. ( 28984013 )
2018
13
Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. ( 29373977 )
2018
14
Germline JAK2 L611S mutation in a child with thrombocytosis. ( 29567786 )
2018
15
Plateletpheresis: Nonoperative Management of Symptomatic Carotid Thrombosis in a Patient with Reactive Thrombocytosis. ( 29555611 )
2018
16
Platelet Characteristics in Patients with Essential Thrombocytosis. ( 29790256 )
2018
17
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
18
Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment. ( 29633731 )
2018
19
Thrombocytosis in children: Clinico-hematological profile from a single centre in Eastern India. ( 29403202 )
2018
20
The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis. ( 29654963 )
2018
21
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report: Erratum. ( 29979453 )
2018
22
Jak-2 mutation frequency in patients with thrombocytosis. ( 29732039 )
2018
23
Integrated micro/messenger RNA regulatory networks in essential thrombocytosis. ( 29420626 )
2018
24
Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. ( 29760805 )
2018
25
Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia. ( 29668550 )
2018
26
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. ( 29442537 )
2018
27
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
28
Therapeutic Thrombocytapheresis for Symptomatic Thrombocytosis in Hemato-Oncology Patients. ( 29205870 )
2018
29
Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. ( 29537938 )
2018
30
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
31
Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. ( 30416171 )
2018
32
Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis. ( 30526151 )
2018
33
Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report. ( 30524760 )
2018
34
Myelodysplastic syndrome with fibrosis and complex karyotype arising in a patient with essential thrombocythaemia. ( 30173238 )
2018
35
Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis. ( 30370419 )
2018
36
Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis. ( 30097170 )
2018
37
Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis - Does MTHFR Polymorphism Matter. ( 30140211 )
2018
38
A case of SF3B1 positive myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. ( 30468430 )
2018
39
Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis. ( 30479089 )
2018
40
Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer. ( 30178070 )
2018
41
Herbaspirillum huttiense pneumonia in a patient with essential thrombocythaemia. ( 30556384 )
2018
42
Thrombocytosis and portal vein thrombosis after splenectomy for paediatric haemolytic disorders: How should they be managed? ( 30246317 )
2018
43
Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis. ( 30218421 )
2018
44
Prevalence of thrombocytopenia and thrombocytosis upon acute hospital admission to internal medicine units. A cross-sectional study in Denmark. ( 30177488 )
2018
45
Potential cardiac consequences of thrombocytopenia and thrombocytosis. ( 30290370 )
2018
46
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. ( 28169426 )
2018
47
Thrombocytosis and central nervous system involvement in a case of canine acute megakaryoblastic leukemia. ( 30024652 )
2018
48
Preoperative thrombocytosis in surgically treated patients with non-small cell lung cancer. ( 30057382 )
2018
49
The prognostic role of pretreatment thrombocytosis in gastric cancer: A systematic review and meta-analysis. ( 30075601 )
2018
50
Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome. ( 30186759 )
2018
Sources

Variations for Thrombocytosis

About this section
Sources

Expression for Thrombocytosis

About this section
Search GEO for disease gene expression data for Thrombocytosis.
Sources

Pathways for Thrombocytosis

About this section

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 64
Show member pathways
 13.43 CSF2 EPO F2 IL11 IL3 IL6
2
TGF-Beta Pathway 64
Show member pathways
 13.36 EPO F2 IL11 IL3 IL6 JAK2
3
Akt Signaling 64
Show member pathways
 13.26 CSF2 IL11 IL3 IL6 JAK2 THPO
4
PAK Pathway 64
Show member pathways
 13.14 CSF2 IL11 IL3 IL6 JAK2 THPO
5
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.99 CSF2 F2 F3 IL3 JAK2 MPL
6
p70S6K Signaling 64
Show member pathways
 12.9 F2 IL3 IL6 JAK2 THPO
7
Kit receptor signaling pathway 1
Show member pathways
 12.03 EPO IL3 JAK2
8
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 12.02 F2 F3 SERPINC1
9
G beta-gamma signalling through PI3Kgamma 66
Show member pathways
 12 CSF2 IL3 JAK2
10
Complement and coagulation cascades 1 37
11.96 F2 F3 SERPINC1
11
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.95 IL11 IL3 IL6 JAK2 THPO
12
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.94 IL11 IL3 IL6 THPO
13
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 11.92 CSF2 EPO IL11 IL3 IL6 JAK2
14
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.9 CSF2 F2 IL6
15
AGE-RAGE signaling pathway in diabetic complications 37
11.78 F3 IL6 JAK2
16
Integrin alphaIIb beta3 signaling 66
Show member pathways
 11.77 F2 MPL THPO
17
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.74 CSF2 IL6 JAK2
18
Jak-Stat Signaling Pathway (sino) 67
11.74 EPO IL3 IL6 JAK2
19
Visual Cycle in Retinal Rods 64
11.73 CRP JAK2 MPL THPO
20
Rheumatoid arthritis 37
11.71 CSF2 IL11 IL6
21
IL6-mediated signaling events 1
Show member pathways
 11.69 CRP IL6 JAK2
22
Hematopoietic cell lineage 37
11.62 CSF2 EPO IL11 IL3 IL6 THPO
23
Interleukin-6 family signaling 66
Show member pathways
 11.5 IL11 IL6 JAK2
24
Differentiation Pathway 1
11.39 EPO IL11 IL3 IL6
25
Hematopoietic Stem Cell Differentiation 1
11.35 CSF2 EPO IL3 IL6
26
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.23 CSF2 EPO IL11 IL3 IL6 MPL
27
Development_Thrombopoetin signaling via JAK-STAT pathway 22
11.14 CRP JAK2 MPL THPO
28
Cytokines and Inflammatory Response 1
11.09 CSF2 IL11 IL3 IL6
29
G-protein signaling_RhoB regulation pathway 22
11.08 CSF2 IL11 IL3 IL6
30
Overview of nanoparticle effects 1
10.91 CRP IL6
31
G-protein signaling_Rap2B regulation pathway 22
10.87 CSF2 IL11 IL3 IL6 THPO
Sources

GO Terms for Thrombocytosis

About this section

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRP CSF2 EPO F2 F3 IL11
2 extracellular space GO:0005615 9.36 CRP CSF2 EPO F2 F3 IL11

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.8 CSF2 EPO F2 IL11 IL3 IL6
2 blood coagulation GO:0007596 9.73 F2 F3 JAK2 SERPINC1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL11 IL3 IL6 JAK2
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 F2 JAK2 SELP
5 hemostasis GO:0007599 9.63 F2 F3 SERPINC1
6 acute-phase response GO:0006953 9.62 CRP EPO F2 IL6
7 positive regulation of cell proliferation GO:0008284 9.56 CSF2 EPO F2 IL11 IL3 IL6
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 CSF2 EPO IL3 IL6 JAK2
9 myeloid cell differentiation GO:0030099 9.54 TET2 THPO
10 interleukin-6-mediated signaling pathway GO:0070102 9.52 IL6 JAK2
11 regulation of blood coagulation GO:0030193 9.51 F2 SERPINC1
12 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
13 thrombopoietin-mediated signaling pathway GO:0038163 9.4 MPL THPO
14 cytokine-mediated signaling pathway GO:0019221 9.17 CSF2 F3 IL11 IL3 IL6 JAK2

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 EPO IL11 IL3 IL6 THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 JAK2
3 growth factor activity GO:0008083 9.1 CSF2 F2 IL11 IL3 IL6 THPO
Sources

Sources for Thrombocytosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....